Navigation Links
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Date:9/26/2007

ach of its clinical and preclinical product candidates. The company is currently evaluating promising inhibitors of CXCR7 in preclinical studies.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on their proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
3. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
4. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
5. Gene-Specific Primers for NMDA Receptor Subunits
6. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
7. Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer
8. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
9. Performance of Ad-A-Gene EGFP-Glucocorticoid Receptor (EGFP-GCCR): an adenoviral vector gene delivery system
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 July 30, 2014. ... a biotechnology firm that provides DNA-based authentication and security ... Ph.D. Vice President of Life Sciences, a newly created ... , Dr. Hogan will lead APDN’s drive to build ... with biotech and healthcare customers, provide guidance to APDN’s ...
(Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
(Date:7/30/2014)... Edwardsville, IL (PRWEB) July 30, 2014 ... Dr. Arun Athmanathan will present his findings on ... of Energy conference this week in Washington, D.C. ... Department of Energy conference is a testament to ... Director John Caupert said. “Thanks to the foresight ...
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
... July 28 VIASPACE Inc. (OTC Bulletin Board: ... a low-carbon, renewable biomass crop, reported that Chief Executive Dr. ... Third Annual World Congress of Industrial Biotechnology held in ... than 500 business executives, industry leaders, technical experts, government officials ...
... July 27 ITelagen, a leading provider of electronic health record ... Asthma Associates of Northern California , San Jose, CA ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... , , ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 2VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 3VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 4Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 2Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 3
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... Laboratory has received a pledge of $1 million from ... the Laboratory,s new Neurobehavioral Biometry Center. , ... will enable the Laboratory to develop a greater breadth ... ultimate goal of accelerating the pace of research to ... as a premier resource for the Laboratory and its ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Hopkins researchers say they have discovered a cause-and-effect ... schizophrenia previously believed to be independent of one ... to develop better drugs to treat the cognitive ... illnesses. ,Researchers have long studied the role ...
... 2012 The University of Miami (UM) Rosenstiel School of ... 2012-2013 Alumni Awards. The grantees were selected by a ... more than $11,000 in funds. , "We received 30 applications ... biology to meteorology," said Laura Bracken Chaibongsai, Alumni & Outreach ...
... place certain types of living cells on a microscope slide, ... and assemble themselves into a simple, if primitive tissue. A ... and then some, about the mechanical structure and behavior of ... Proceedings of the National Academy of Sciences , chemical ...
Cached Biology News:Johns Hopkins researchers link 2 biological risk factors for schizophrenia 2Recipients of UM Rosenstiel School's 2012-2013 Alumni Awards announced 2Force of nature: Defining the mechanical mechanisms in living cells 2Force of nature: Defining the mechanical mechanisms in living cells 3Force of nature: Defining the mechanical mechanisms in living cells 4
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
... GI Number: 4503277 Accession Number: ... FUNCTION: Supplies the nucleotide substrate for ... H 2 O = dUMP + ... Belongs to the Diseases: Benign Tumor; ...
Biology Products: